990 trials (keyword fallback)
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Monoclonal Gammopathy of Undetermined Significance · Multiple Myeloma · Smoldering Multiple Myeloma
Primary: Changes in M-protein Levels — 1.65; 2.24 g/dL — p=.23
Plasma Cell Disorder
Primary: Positive for Hepatitis B Surface Antigen — 4; 3 participants
Reproductive Sterility
Primary: Number of Control and Treated Participants With Successful Live Births Following Conventional IVF or ICSI Cycles — 18; 13; 8; 9 participants
Vitamin B12 Deficiency
Primary: Prevalence of Vitamin B12 Deficiency — 3; 6; 4 participants
Cervical Abnormalities · Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Cancer
Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…
Cervical Intraepithelial Neoplasia
Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants
Influenza · Multiple Myeloma · Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Treatment Failure by Primary Endpoint — 26; 13 Participants
Prostate Cancer · Multiple Myeloma · Smoldering Multiple Myeloma (SMM)
Primary: Response Rate of Curcumin & Piperine Supplementation in Patients on Active Surveillance for Either Early Stage Prostate Cancer or Patients on Observation for…
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA — 34 Gy - MTD
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose Limiting Toxicities — 0; 0; 1 Participants
Neuroblastoma
Primary: Efficacy at Completion of Treatment
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
COVID-19 · Sars-CoV2
Primary: Number of Samples Tested — 3692 samples